Talk:Reshma Kewalramani#Updates to Boards and awards

{{edit COI|P}}

Hi. I am John and I would like to request the following update and corrections to Reshma Kewalramani's page.

• Kewalramani's year of birth is incorrect in two places; please change it to 1972 in the lead and in the Early life sections. This is the source. https://investors.vrtx.com/static-files/7bf5f528-b4ed-45c4-893d-bf9d98a53bb1. On page 24 of this source her age is listed as 49. Since the document is dated Dec. 31, 2021, that means that there is no ambiguity about how old she is on any day in 2021, even if her birthday is Dec. 31st, as of that last day of 2021 she was 49.
• Please add the following paragraph to the end of the first paragraph of the Career section: Since she became CEO, Vertex has continued to research and develop therapies for multiple diseases including moving its cystic fibrosis,{{Cite news |last=Choudhary |first=Vidhi |date=10 March 2022 |title=Vertex Pharma Has a Cystic Fibrosis Drug That Rivals Envy |work=TheStreet |url=https://www.thestreet.com/technology/vertex-pharma-has-a-blockbuster-drug-that-rivals-envy}} type 1 diabetes,{{Cite news |last=Jason |first=Mast |date=24 March 2021 |title=Inside Vertex 3.0: Can Reshma Kewalramani repeat one of biotech's biggest success stories 'again and again and again'? |work=Endpoints News |url=https://endpts.com/inside-vertex-3-0-can-reshma-kewalramani-repeat-one-of-biotechs-biggest-success-stories-again-and-again-and-again/}} APOL1-mediated kidney disease{{Cite news |last=Armstrong |first=Madeleine |date=1 December 2021 |title=Vertex finally catches a break |work=Evaluate Vantage |url=https://www.evaluate.com/vantage/articles/news/trial-results/vertex-finally-catches-break}}{{Cite news |last=Pagliarulo |first=Ned |date=22 March 2022 |title=Vertex plans path to FDA for top drug prospect |work=BioPharmaDive |url=https://www.biopharmadive.com/news/veretx-apol1-kidney-pivotal-clinical-trial/620785/}} and pain programs into the clinic.{{Cite news |last=Fidler |first=Ben |date=22 September 2021 |title=This is the time to double down': Top Vertex executives defend research plan as pressure builds |work=BioPharmaDive |url=https://www.biopharmadive.com/news/vertex-pressure-research-kewalramani-investors/606763/}} The company has also partnered with CRISPR Therapeutics to develop gene-editing therapies for the treatment of sickle cell disease and beta thalassemia.{{cite news |last1=Garde |first1=Damian |title=A CRISPR treatment for blood diseases shows curative promise in small study |url=https://www.statnews.com/2021/06/11/crispr-treatment-blood-diseases-curative-promise-small-study/ |publisher=STAT News |date=11 June 2021}}
• In the Personal life section, please remove "a daughter and" because Reshma only has twin sons and no daughter; there is no source that says she has a daughter.

{{reflist-talk}}

Thank so much for your help, JohnDatVertex (talk) 17:40, 8 April 2022 (UTC)

:File:Yellow check.svg Partly done: Removed the year, given the source did not include it. Neither did it give a date, so it's best to not include a DOB until a reliable source is provided (yours isn't independent). Added your requested paragraph, with substantial edits, and also withdrew the daughter statement. PK650 (talk) 23:20, 18 April 2022 (UTC)

::Thanks so much {{u|PK650}} for implementing my above edit request. However, the incorrect birth year also appears at the beginning of the "Early life" section, and should be removed from there as well. The article was also incorrectly added to the "1973 births" category, so that incorrect category should also be removed.

::One additional request I have is to remove the mention of "RIZE Massachusetts" in the Boards and awards section, since she no longer is a board member there. You can check that here: https://www.rizema.org/board/

::One last issue is that reference #14 has a "Cite error" warning, which should probably be fixed. Once again, thanks so much for your help. JohnDatVertex (talk) 12:45, 20 April 2022 (UTC)

:::Thank you for letting me know. Fixed. PK650 (talk) 01:02, 23 April 2022 (UTC)

::::Thanks again {{u|PK650}} for your edits. Now that the incorrect birthday has been removed entirely from the article, I hope you don’t mind if I remove the category template "1973 births" directly. Thanks again. JohnDatVertex (talk) 12:58, 25 April 2022 (UTC)

{{edit COI|A}}

Hi. The "Boards and awards" section needs updating with the following sourced content:

• Please add the following as a new first paragraph to the Boards and awards section:

:Kewalramani is a member of the Massachusetts General Hospital Board of Trustees, the Biomedical Science Careers Program Board{{cite web |title=Leadership |url=https://www.bscp.org/about-bscp/leadership/ |website=BSCP.com}} and the Boston University School of Medicine Dean's Advisory Board.{{cite web |title=Giving/Board of Trustees |url=https://giving.massgeneral.org/trustees |website=giving.massgeneral.org}}{{cite web |title=BUSM Dean’s Advisory Board |url=https://www.bumc.bu.edu/busm/giving/who-gives/busm-deans-advisory-board/ |website=bumc.bu.edu}} She is also a member of the board of directors of Ginkgo Bioworks,{{cite web |title=Vertex CEO Dr. Kewalramani to Join Ginkgo Board |url=https://www.ginkgobioworks.com/2021/08/03/kewalramani-joins-board/ |website=ginkgobioworks.com |publisher=Ginkgo Bioworks |date=3 August 2021}} and was on the inaugural board of directors of the Kidney Health Initiative.{{cite news |title=Dr. Reshma Kewalramani named incoming president and CEO of Vertex Pharmaceuticals, former member ASN KHI Board of Directors |url=https://www.kidneynews.org/view/post/research-10/dr.-reshma-kewalramani-named-incoming-president-and-ceo-of-vertex-pharmaceuticals--former-member-asn-khi-board-of-directors.xml |publisher=Kidney News Online |date=26 July 2019}}

• Please remove the following sentence from the already existing paragraph, (what is now the second paragraph), since this information is included in the new first paragraph above:

:"She is a member of the board of directors of the Biomedical Science Careers Program and sits on the Boston University School of Medicine Dean's Advisory Committee."

• Please add the following to the end of the second paragraph: (the pre-existing paragraph-change the period after the word Indiaspora to a comma):

:Business Insider’s list of 10 people transforming health care,{{cite news |last1=Lee |first1=Vivian S. |title=100 People Transforming Business in North America |url=https://www.businessinsider.com/tb/the-list-of-300-people-transforming-business-in-north-america-2020-9#_healthcare |publisher=Business Insider |date=2020}} the PharmaVOICE 100 list of leaders in the life sciences,{{cite news |title=PharmaVOICE 100 Who’s on the List - By Category |url=https://www.pharmavoice.com/news/2020-07-pharmavoice100-category/612225/ |publisher=PharmaVOICE |date=1 August 2020}} and Boston Business Journal’s list of Women Who Mean Business.{{cite news |title=Here are the BBJ's 2020 Women Who Mean Business honorees |url=https://www.bizjournals.com/boston/news/2020/10/15/bbj-2020-women-who-mean-business-honorees.html |publisher=Boston Business Journal |date=15 October 2020}} In 2021, she was the recipient of the International Institute of New England’s Golden Door Award and was named a New Englander of the Year by the New England Council.{{cite news |title=NEC to Honor Historic All-Female Lineup of 2021 New Englanders of the Year |url=https://newenglandcouncil.com/press-release/nec-to-honor-historic-all-female-lineup-of-2021-new-englanders-of-the-year/ |publisher=The New England Council |date=2021}} Under her leadership as CEO, Vertex was ranked #2 on The Commonwealth Institute’s Top Women-Led Businesses in Massachusetts in 2021.{{cite news |title=The 2021 Top 100 Women-Led Businesses |url=https://www.bostonglobe.com/2021/11/05/magazine/2021-top-100-women-led-businesses-massachusetts/ |publisher=Boston Globe |date=5 November 2021}}

{{reflist-talk}}

Thanks so much. I am pinging {{u|PK650}} who has been helpful in the past. JohnDatVertex (talk) 19:21, 12 May 2022 (UTC)

: {{done}} -Kj cheetham (talk) 10:34, 9 July 2022 (UTC)

::Hi {{u|Kj cheetham}}, Thanks for implementing my edit request, and inviting me to learn more about editing Wikipedia. I don’t know if I will ever have the time to contribute more to Wikipedia, but it is certainly something I will consider. With appreciation, JohnDatVertex (talk) 18:58, 11 July 2022 (UTC)

Hi. I noticed the new Infobox and decided to fix it up a bit, including adding some information. I am happy to discuss if anyone has any questions. JohnDatVertex (talk) 20:41, 30 January 2024 (UTC)

{{edit COI|d}}

Hi. Please make the following updates to the Boards and awards sub-head found in the Career section:

• Please add the following as a new paragraph to the beginning of the Boards and Awards section:

::In 2023, Kewalramani was the recipient of the Harvard Business School Alumni Achievement Award,{{Cite web |date=2023 |title=2023 Alumni Achievement Awards |url=https://www.alumni.hbs.edu/Documents/Awards/AAA23_Brochure.pdf |website=Harvard Business School}} the Alan E. Lewis Alnoba CEO Social Leadership Award,{{cite news |last1=Walrath |first1=Rowan |title=Reshma Kewalramani aims to imbue Vertex with 'a sense of responsibility' |url=https://www.bizjournals.com/boston/news/2023/09/07/reshma-kewalramani-social-leadership-award.html |publisher=Boston Business Journal |date=6 September 2023}}{{cite news |last1=Welker |first1=Grant |title=CEO social leadership award, best corporate-nonprofit partnerships named |url=https://www.bizjournals.com/boston/news/2023/07/20/ceo-social-leadership-community-collaboration-awar.html |publisher=Boston Business Journal |date=21 July 2023}} and the India New England Lifetime Achievement Award in 2024.{{Cite web |last= |first= |date=2024-09-26 |title=Inspired to Improve Patients’ Lives, Vertex Pharmaceuticals CEO Reshma Kewalramani to Be Honored With the Lifetime Achievement Award 2024 |url=https://indianewengland.com/inspired-to-improve-patients-lives-vertex-pharmaceuticals-ceo-reshma-kewalramani-to-be-honored-with-the-lifetime-achievement-award-2024/ |access-date= |website=INDIA New England News |language=en}} In 2023 and 2024 she was included in the list of Fortune's 100 "Most Powerful Women,"{{cite web |title=Most Powerful Women |url=https://fortune.com/ranking/most-powerful-women/2023/reshma-kewalramani/ |website=Fortune}}{{Cite web |title=Reshma Kewalramani {{!}} 2024 Most Powerful Women |url=https://fortune.com/ranking/most-powerful-women/2024/reshma-kewalramani/ |access-date=2024-10-20 |website=Fortune |language=en}} and on Boston Magazine's list of "The 150 Most Influential Bostonians."{{cite web |title=The 150 Most Influential Bostonians |url=https://www.bostonmagazine.com/boston-power-list-2023/ |website=www.bostonmagazine.com |date=2023}}{{cite web |title=The 150 Most Influential Bostonians:2024 |url=https://www.bostonmagazine.com/boston-power-list-2024/ |website=www.bostonmagazine |date=23 April 2024}} She was named to Barron's annual list of top CEOs in 2024.{{Cite news |last=Nathan-Kazis |first=Josh |date=21 June 2024 |title=Reshma Kewalramani Is Guiding Vertex Pharmaceuticals to Its Next Big Thing |url=https://www.barrons.com/articles/vertex-pharmaceuticals-reshma-kewalramani-top-ceo-stock-price-54b64a0d}}

• In the first sentence of what was the first paragraph (but is now the second) please add directly after "Board of Trustees" the following:

::the National Board of Directors for Year Up, {{cite web |title=Vertex CEO Reshma Kewalramani, MD’98, Receives 2023 Distinguished Alumni Award |url=https://www.bumc.bu.edu/camed/2023/10/05/vertex-ceo-reshma-kewalramani-md98-receives-2023-distinguished-alumni-award/ |website=www.bumc.bu.edu/}}{{cite web |title=Year Up Appoints Three New Members to Its National Board of Directors |url=https://www.yearup.org/about/newsroom/press/year-appoints-three-new-members-its-national-board-directors |website=www.yearup.org}}

• In the same paragraph, in the last sentence, please remove "Ginkgo Bioworks" as she is no longer associated with this organization, and change the sentence to the following using the source that is there now:

::She was on the inaugural board of directors of the Kidney Health Initiative.

• In the third paragraph, (which was the second paragraph) at the end of the third sentence, directly after "Boston Business Journal's Power 50" add the following with new sources to update:

::in 2022, 2023 and 2024.{{Cite web |last=Welker |first=Grant |date=28 September 2022 |title=BBJ announces the Power 50: Movement Makers honorees for 2022 |url=https://www.bizjournals.com/boston/news/2022/09/28/business-journal-announces-its-2022-power-50.html |access-date=2024-10-20 |website=www.bizjournals.com}} {{cite news |last1=Walker |first1=Grant |title=Boston Business Journal unveils its 2023 Power 50 |url=https://www.bizjournals.com/boston/news/2023/09/21/boston-business-journal-unveils-its-2023-power-50.html |publisher=Boston Business Journal |date=21 September 2023}}{{Cite web |last=Welker |first=Grant |date=23 September 2024 |title=Boston Business Journal unveils 2024 Power 50 |url=https://www.bizjournals.com/boston/news/2024/09/23/boston-business-journal-unveils-2024-power-50.html |access-date= |website=www.bizjournals.com}}

• Please replace the last sentence of the third paragraph (originally the second paragraph) with the following sentence: (I am only adding the years and rankings, plus the new name for the Commonwealth Institute. It seems easier to describe how to make the changes by just replacing with the following sentence):

::Under her leadership as CEO, Vertex was ranked #2 on The Women's Edge, (formerly The Commonwealth Institute) Top Women-Led Businesses in Massachusetts in 2021,{{cite news |title=The 2021 Top 100 Women-Led Businesses |url=https://www.bostonglobe.com/2021/11/05/magazine/2021-top-100-women-led-businesses-massachusetts/ |publisher=Boston Globe |date=5 November 2021}} #4 in 2022, {{cite news |title=The Top 100 Women-Led Businesses in Massachusetts 2022 |url=https://www.bostonglobe.com/2022/10/28/magazine/top-100-women-led-businesses-massachusetts-2022/ |publisher=The Boston Globe |date=28 October 2022}} and #1 in 2023. {{cite news |title=The Top 100 Women-Led Businesses in Massachusetts in 2023 |url=https://www.bostonglobe.com/2023/11/03/magazine/this-years-top-100-women-led-businesses-in-massachusetts/ |publisher=The Boston Globe |date=4 November 2023}}

{{reflist-talk}}

Pinging {{u|PK650}} and {{u|Kj_cheetham}} who have been active on this page in the past. Thanks so much. JohnDatVertex (talk) 19:20, 12 November 2024 (UTC)

:Hi. Thanks for the ping. This is not exactly my area of expertise. I'm of the opinion a lot of these are probably not particularly notable, and so I would probably defer to someone who specializes in CORP type articles. PK650 (talk) 09:40, 14 November 2024 (UTC)

::{{respond|xmark|Not Done}}. Non notable and purely promotional in intent. If the requesting editor wishes to create a hagiography then please set up a website specifically for that purpose rather than attempting to use an encyclopaedia for promotion. Axad12 (talk) 10:50, 2 January 2025 (UTC)

{{Edit COI|answered=yes}}

• The following is a slightly re-written version of the second paragraph of the Career section, which adds some recent developments, and simplifies some of the language of the previous paragraph. If you agree with the changes, please just replace the current paragraph with the update as follows:

:Since Kewalramani became CEO,{{Cite web |last=M.D |first=Chase Feiger |date=14 March 2024 |title=Vertex Is Writing A New Playbook For Pharma R&D. And It’s Working. |url=https://www.forbes.com/sites/chasefeiger/2024/05/14/vertex-is-writing-a-new-playbook-for-pharma-rd-and-its-working/ |access-date= |website=Forbes |language=en}} Vertex has continued to develop and secure approvals for cystic fibrosis therapy drugs Trikafta{{Cite news |last=Nadeem |first=Dania |date=9 June 2021 |title=Vertex cystic fibrosis treatment gets U.S. nod for use in children aged 6-11 |url=https://www.reuters.com/business/healthcare-pharmaceuticals/vertex-cystic-fibrosis-treatment-gets-us-approval-use-6-11-year-olds-2021-06-09/ |archive-url=http://web.archive.org/web/20230216183247/https://www.reuters.com/business/healthcare-pharmaceuticals/vertex-cystic-fibrosis-treatment-gets-us-approval-use-6-11-year-olds-2021-06-09/ |archive-date=2023-02-16 |access-date= |work=Reuters |language=en-US}}{{Cite web |last=Kang |first=Jaymin |date=2 January 2025 |title=FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta |url=https://www.clinicaladvisor.com/news/fda-approval-increases-eligibility-for-cystic-fibrosis-medication-trikafta/ |access-date= |website=Clinical Advisor |language=en-US}}{{Cite web |last=Choudhary |first=Vidhi |date=10 March 2022 |title=Biotech Vertex Pharma Has a Blockbuster Drug That Rivals Envy |url=https://www.thestreet.com/technology/vertex-pharma-has-a-blockbuster-drug-that-rivals-envy |access-date= |website=TheStreet |language=en-us}} and Alyftrek.{{Cite web |last=Liu |first=Angus |date=23 December 2024 |title=Vertex wins FDA nod for once-daily cystic fibrosis triplet |url=https://www.fiercepharma.com/pharma/vertex-snags-fda-nod-once-daily-cystic-fibrosis-triplet-alyftrek-switch-trikafta-kicks |access-date= |website=www.fiercepharma.com |language=en}}{{Cite web |last=Lobo |first=Andrea |date=9 March 2025 |title=Alyftrek, triple-combination CF treatment, approved in UK |url=https://cysticfibrosisnewstoday.com/news/alyftrek-triple-combination-cf-treatment-approved-uk/ |access-date= |website=cysticfibrosisnewstoday.com |language=en-US}} Under her leadership,{{cite news |last1=Mullin |first1=Emily |title=The World’s First Crispr Drug Gets a Slow Start |url=https://www.wired.com/story/the-worlds-first-crispr-drug-gets-a-slow-start-sickle-cell-beta-thalassemia-vertex/ |publisher=Wired |date=23 December 2024}} and in partnership with CRISPR Therapeutics, Vertex developed Casgevy, the first CRISPR-based gene-editing therapy for sickle cell disease and beta thalassemia,{{Cite news |last=Mullin |first=Emily |date=23 December 2024 |title=The World’s First Crispr Drug Gets a Slow Start |url=https://www.wired.com/story/the-worlds-first-crispr-drug-gets-a-slow-start-sickle-cell-beta-thalassemia-vertex/ |access-date= |work=Wired |language=en-US |issn=1059-1028}}{{Cite web |last=Garde |first=Damian |date=11 June 2021 |title=A CRISPR treatment for blood diseases shows curative promise in small study |url=https://www.statnews.com/2021/06/11/crispr-treatment-blood-diseases-curative-promise-small-study/ |access-date= |website=STAT |language=en-US}}{{Cite journal |last=Sheridan |first=Cormac |date=21 November 2023 |title=The world’s first CRISPR therapy is approved: who will receive it? |url=https://www.nature.com/articles/d41587-023-00016-6 |journal=Nature Biotechnology |language=en |volume=42 |issue=1 |pages=3–4 |doi=10.1038/d41587-023-00016-6}} approved for patients in December 2023; and advanced cell therapies for type 1 diabetes.{{Cite web |last=Priyan |first=Vishnu |date=24 June 2024 |title=Vertex's VX-880 shows promise in Phase I/II type 1 diabetes trial |url=https://www.clinicaltrialsarena.com/news/vertex-type-1-diabetes-trial/ |access-date= |website=Clinical Trials Arena |language=en-US}}{{Cite web |last=Branca |first=Malorye |date=25 June 2024 |title=Islet Cell Therapy Breaks Through: Three Patients Become Insulin Independent in Vertex Type 1 Diabetes Trial |url=https://www.insideprecisionmedicine.com/topics/precision-medicine/islet-cell-therapy-breaks-through-three-patients-become-insulin-independent-in-vertex-type-1-diabetes-trial/ |access-date= |website=Inside Precision Medicine |language=en-US}} She is leading the company through clinical trials for the treatment of APOL1-mediated kidney disease (AMKD), and others.{{Cite web |last=Pagliarulo |first=Ned |date=22 March 2022 |title=Vertex plans path to FDA for top drug prospect |url=https://www.biopharmadive.com/news/veretx-apol1-kidney-pivotal-clinical-trial/620785/ |access-date= |website=BioPharma Dive |language=en-US}}{{Cite web |last=Alvarado |first=Delilah |date=1 April 2024 |title=Vertex moves kidney disease drug into late-stage testing |url=https://www.biopharmadive.com/news/vertex-apol1-kidney-inaxaplin-phase-3/711845/ |access-date= |website=BioPharma Dive |language=en-US}} In 2025, the FDA approved Journavx (suzetrigine) for moderate-to-severe acute pain, the first new class of pain medication to be approved by the FDA in over 20 years.{{Cite web |last=Goodman |first=Brenda |date=30 January 2025 |title=FDA approves first new type of pain medication in 25 years |url=https://edition.cnn.com/2025/01/30/health/fda-approves-painkiller-suzetrigine-journavx/index.html |access-date= |website=CNN |language=en}}{{Cite news |last=Smith-Schoenwalder |first=Cecelia |date=21 January 2025 |title=What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA |url=https://www.usnews.com/news/health-news/articles/2025-01-31/what-to-know-about-journavx-the-non-opioid-pain-medication-just-approved-by-the-fda#google_vignette |work=US News}}

• Please also add the following to the end of the Boards and awards section:

:In 2025, Time magazine included Kewalramani on its list of "100 Most Influential People." {{cite news |title=The 100 Most Influential People of 2025 |url=https://time.com/collections/100-most-influential-people-2025/?filters=leaders |publisher=Time |date=2025}}{{cite news |last1=Kumar |first1=Arun |title=Reshma Kewalramani among 2025 Time 100 most influential people |url=https://americanbazaaronline.com/2025/04/17/reshma-kewalramani-among-2025-time-100-most-influential-people-461900/ |publisher=americanbazaaronline.com |date=17 April 2025}}{{cite news |last1=Vashistha |first1=Aashish |title=Who is Reshma Kewalramani, the Indian-Origin biotech trailblazer on TIME's list? |url=https://www.indiatoday.in/world/us-news/story/who-is-reshma-kewalramani-the-indian-origin-biotech-trailblazer-on-times-list-glbs-2710198-2025-04-17 |publisher=India Today |date=17 April 2025}}

{{reflist-talk}}

Thanks so much for your help. JohnDatVertex (talk) 16:49, 5 May 2025 (UTC)

: I have added updated second paragraph with a somewhat less hyped version. While the CEO is important, so are the rest of the employees that contributed to the companies achievements. I have also added the Time's list of 100 of the most influential people. Boghog (talk) 19:48, 8 May 2025 (UTC)

::Thanks so much {{u|Boghog}} for implementing the edit request. All the best, JohnDatVertex (talk) 21:09, 20 May 2025 (UTC)

:{{Respond|yellowclock|Already done}} Marking the edit request as closed. Sammi Brie (she/her · t · c) 07:34, 21 May 2025 (UTC)